| 7 | Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?显示文摘Liver injury has been reported in coronavirus disease 2019(COVID-19)cases but the impact of pre-existing liver damage and related etiology have not been completely elucidated.Our research interests include the potential reciprocal influence of COVID-19 and pre-existing liver damage related to hepatitis C virus(HCV)infection,in particular.To this end,we have evaluated three cohorts of patients admitted at three Italian hospitals during the coronavirus pandemic;these included 332 patients with COVID-19 and 1527 patients with HCV who were from established real-world antiviral treatment study cohorts(sofosbuvir/velpatasvir),with either liver disease(various severities;n=1319)or cirrhosis(n=208).Among the COVID-19 patients,10 had cirrhosis(3%),including 7 of metabolic origin and 3 of viral origin.Mortality among the COVID-19 patients was 27.1%,with 70%of those with cirrhosis of metabolic etiology having died.Cirrhosis,older age,low white blood cell count and lymphocyte count being identified as risk predictors of death[odds ratio(OR)=13.7,95%confidence interval(CI):2.59-83.01,P=0.006;OR=1.05,95%CI:1.03-1.08,P=0.0001;OR=1.09,95%CI:1.36-1.16,P=0.001;OR=0.61,95%CI:0.39-0.93,P=0.023,respectively].In the two cohorts of HCV patients,COVID-19 diagnosis was made in 0.07%of those with liver disease and 1%of those with cirrhosis.Thus,the prevalence of HCV antibodies among COVID-19-infected patients was comparable to that currently reported for the general population in Italy.Amongst the COVID-19 patients,pre-existing metabolic cirrhosis appears to be associated with higher mortality,while HCV antibodies may be suggestive of“protection”against COVID-19. | Alessandra Mangia Giovanni Cenderello Gabriella Verucchi Alessia Ciancio Andrea Fontana Valeria Piazzolla Nicola Minerva Maria Maddalena Squillante Massimiliano Copetti | 2020 | World Journal of Clinical Cases2020，8，22： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员